8-K: Klotho Neurosciences Secures Exclusive Global Gene Therapy Platform License from AAVnerGene

Klotho Neurosciences, Inc. has entered into an exclusive global agreement with AAVnerGene Inc. to utilize its AAVone platform for the development and commercialization of three human Klotho gene therapy programs.

Summary

• Klotho Neurosciences, Inc. (KLTO) entered into a Terms of Agreement with AAVnerGene Inc. on July 16, 2025, granting exclusive and global rights to use AAVnerGene's AAVone platform.
• The agreement covers the development, manufacturing, and commercialization of gene therapy products based on human Klotho gene isoforms for three clinical programs: KLTO-101 (CNS-targeted secreted Klotho for Alzheimer's and ALS), KLTO-202 (Neuromuscular-targeted secreted Klotho for ALS and other motor neuron diseases), and KLTO-303 (Full-length human soluble-Klotho for aging-related pathologies).
• Initial license fees scale from a total of $250,000 for the first product to $500,000 for the third product.
• Specific upfront fees for the preclinical license stage and tech transfer include $150,000 for KLTO-202, $200,000 for KLTO-101, and $300,000 for KLTO-303, plus tech transfer fees of $100,000 for KLTO-202, $100,000 for KLTO-101, and $200,000 for KLTO-303.
• Additional milestone-based clinical license fees apply: $150,000 to $300,000 upon IND filing and Phase I/II trials, $150,000 to $300,000 upon completion of six months of dosing in Phase III, and $1,000,000 to $2,000,000 one month post BLA approval.
• A 2% royalty on net sales of licensed AAVone-based commercial products will be paid.
• The agreement outlines the scope for AAVone production, including subcloning, procedure optimization, 5L-scale production, QC release, and stability programs for KLTO-202 and KLTO-101.
• Estimated outsourced CDMO manufacturing costs for a 50L GMP batch are detailed at $2,900,000, covering project management, plasmid establishment, process development, analytical development, cell banking, and engineering runs.

Sentiment

Score: 8

Explanation: This is a highly positive strategic partnership that addresses key challenges in gene therapy (cost, toxicity) and accelerates Klotho's pipeline. The exclusive global rights to a promising platform for multiple programs are significant. The only minor caveats are the 'Terms of Agreement' status and patent risk, but the overall sentiment is strong due to the potential for significant operational and clinical advantages.

Positives

• Secured exclusive and global rights to AAVnerGene's AAVone platform for three critical gene therapy programs.
• The partnership is expected to accelerate product candidates into the clinic at a faster pace.
• Anticipated lower manufacturing costs, higher efficacy, and purity compared to current AAV manufacturing processes.
• AAVnerGene's AAVone system is designed to dramatically drive down manufacturing costs.
• AAVnerGene's ATHENA platform enables highly efficient and specific tissue-targeting, potentially reducing required doses and toxicity.
• The collaboration directly addresses industry bottlenecks of high gene therapy drug prices and dose-related toxicity.
• Focuses on high-unmet-need areas such as neurodegenerative and age-related disorders, including ALS, Alzheimer's, and Parkinson's disease.
• Leverages Klotho's existing data on neuron protection and longevity, enhancing the potential of the gene therapy candidates.

Negatives

• The agreement involves significant financial commitments through initial license fees, escalating milestone payments, and a 2% royalty on net sales.
• The current document is a 'Terms of Agreement,' and a 'Definitive License Agreement' is yet to be drafted, which could introduce further negotiations or changes.
• Monetary payments and terms may be amended if AAVnerGene's core patent applications do not result in a patent being granted and issued.

Risks

• Inability to implement business plans as envisioned.
• Failure to identify and realize additional opportunities.
• Inability to meet or exceed financial projections.
• Changes in the regulatory or competitive environment in which the company operates.
• Actual future events could differ materially from forward-looking statements.
• The core intellectual property of AAVnerGene being licensed is critical, and if patent applications do not result in a patent, the terms of the agreement may be amended.

Future Outlook

Klotho Neurosciences expects this partnership to accelerate its product candidates into the clinic at a faster pace, with lower costs, higher efficacy, and purity, and lower toxicity compared to current AAV manufacturing processes. The company also anticipates exploring other complementary longevity-related assets.

Management Comments

• "We announced previously that we have been looking for a more efficient, next-generation method to manufacture several of our patented gene therapy candidates, and the two platform technologies offered by AAVnerGene will catapult our product candidates into the clinic at a faster pace, at a lower cost, a higher efficacy and purity compared to the current state-of-the-art AAV manufacturing processes." Dr. Joseph Sinkule, CEO of KLTO.
• "AAV gene therapy has been proven to be a revolutionary one-time, life-changing treatment, however it is experiencing some crisis caused by high drug price and high dose-related toxicity. We envisioned these bottleneck problems six years ago and AAVnerGene was founded with the mission to solve them. With the two proprietary platforms, we can dramatically drive down the manufacture cost with the AAVone system and the dose required by the highly efficient and specific tissue-targeting AAVs developed with the ATHENA platform. Its a perfect synergy to partner with Klotho, a neuroscience-driven pathfinder." Dr. Daozhan Yu, Founder and CEO of AAVnerGene.
• "Klotho believes AAVnerGene has conceived a process method that is more cost effective, faster to make, has fewer impurities, shows higher efficacy and lower toxicity because of the higher targeted tissue delivery." Dr. Joseph Sinkule, CEO of KLTO.

Industry Context

The gene therapy industry is currently facing challenges related to high drug prices and dose-related toxicity. This partnership aims to address these critical bottlenecks by leveraging AAVnerGene's AAVone platform for cost-effective, high-yield manufacturing and its ATHENA platform for precise tissue targeting. This strategic move aligns with a broader industry need for more affordable, scalable, and safer gene therapy solutions, particularly for complex neurological diseases, positioning Klotho Neurosciences to potentially overcome significant barriers to widespread adoption and clinical success.

Comparison to Industry Standards

• AAVnerGene's AAVone system is presented as a high-yield, single-plasmid AAV production system that is expected to "dramatically reduce manufacturing costs" compared to current state-of-the-art AAV manufacturing processes.
• The ATHENA platform is described as an advanced capsid engineering platform enabling "precise tissue targeting," which is anticipated to reduce the required dose and associated toxicity, offering a significant advantage over less targeted industry approaches.
• The partnership aims for a "faster pace, at a lower cost, a higher efficacy and purity compared to the current state-of-the-art AAV manufacturing processes," indicating a direct comparison to existing industry benchmarks for AAV gene therapy production.

Stakeholder Impact

• Shareholders: Potential for increased value due to accelerated pipeline development, reduced manufacturing costs, and enhanced product efficacy/safety, leading to a stronger competitive position.
• Patients: Potential for more affordable, effective, and safer gene therapies for devastating neurodegenerative and age-related diseases like ALS, Alzheimer's, and Parkinson's.
• Employees: Potential for increased R&D activity and job stability as the company's pipeline progresses.
• AAVnerGene Inc.: Benefits from licensing revenue (upfront fees, milestones, royalties) and validation of its platform technologies through a partnership with a neuroscience-focused company.

Next Steps

• Drafting of a final definitive License Agreement incorporating the terms of this Agreement.
• Potential funding and operationalization of a second-generation optimization program for KLTO-202.
• Development of KLTO-101 and KLTO-303 once a successful outcome and collaborative relationship has been shown with KLTO-202.
• Future clinical trials (IND filing, Phase I/II, Phase III, BLA approval) for the three gene therapy candidates.
• Exploration of other complementary longevity-related assets.

Key Dates

Recommendation

This strategic partnership is a significant positive catalyst for Klotho Neurosciences. Gaining exclusive global rights to AAVnerGene's AAVone and ATHENA platforms addresses critical bottlenecks in gene therapy manufacturing (cost and toxicity) and promises to accelerate Klotho's three key gene therapy candidates (KLTO-101, KLTO-202, KLTO-303) into the clinic with potentially superior efficacy and safety profiles. This move significantly de-risks the manufacturing aspect of their pipeline and enhances their competitive position in the high-growth gene therapy space, particularly for neurodegenerative diseases. The potential for lower costs and higher efficacy could lead to a substantial market advantage and increased shareholder value.

Keywords

Gene therapy, Klotho, AAVone, AAVnerGene, neurosciences, ALS, Alzheimer's, Parkinson's, motor neuron disease, aging, biotechnology, exclusive license, manufacturing, clinical trials, intellectual property, NASDAQ: KLTO